Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single‐institution study

Documenti analoghi

• Pericardial events associated with ibrutinib‐based therapies for chronic lymphocytic leukaemia in two landmark trials
  di: Bita Fakhri, et al.
  Pubblicazione: (2024)
• Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia
  di: Nilanjan Ghosh, et al.
  Pubblicazione: (2024)
• Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype
  di: Andrea Serafin, et al.
  Pubblicazione: (2025)
• Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia
  di: Tuan Hoang, et al.
  Pubblicazione: (2025)
• Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
  di: M. S. Davids, et al.
  Pubblicazione: (2024)